A peer look on pharmacology of two splendid immunomodulators: Spotlight on ophthalmic approach

Author : Priya Choudhary, R.C. Chaurasia, S.P. Singh, Sudeep Choudhary, Neerjesh, Dharti N

Tacrolimus (FK506) is a novel macrolide immunosuppressant isolated from a strain of Streptomyces and is widely used for transplantation. It has a mechanism of action similar to that of cyclosporine and is a lipophilic molecule which blocks the early phase of T-cell activation, inhibiting both T-lymphocyte signal transduction and IL-2 transcription. Clinical trials of tacrolimus has shown it to be more effective than cyclosporine in liver, kidney, and pulmonary transplantation and lesser toxic than cyclosporine. It impairs prostaglandin synthesis and the release of histamine from mast cells. Thus, it is used in treatment of immune mediated diseases, such as corneal graft rejection, ocular inflammation, and uveitis. In this article, we have reviewed Pharmacology of two chief Immunomodulators and highlightened their role in several conditions such as Keratoconjuctivitis, Graft versus Host Disease and with the special consideration of Ophthalmic uses.

Full Text Attachment

Creative Commons License World Journal of Pharmaceutical Science is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at Permissions beyond the scope of this license may be available at